Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12996MR)

This product GTTS-WQ12996MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12996MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11674MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ858MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ1937MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ8799MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ3590MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ14020MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ13791MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ3815MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BB-10901
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW